KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Edwards Lifesciences (EW) Cost of Revenue (2016 - 2025)

Edwards Lifesciences has reported Cost of Revenue over the past 17 years, most recently at $343.0 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $343.0 million for Q4 2025, up 17.39% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 19.39% YoY), and the annual figure for FY2025 was $1.3 billion, up 19.39%.
  • Cost of Revenue for Q4 2025 was $343.0 million at Edwards Lifesciences, down from $345.2 million in the prior quarter.
  • Over the last five years, Cost of Revenue for EW hit a ceiling of $345.2 million in Q3 2025 and a floor of -$98.8 million in Q4 2022.
  • Median Cost of Revenue over the past 5 years was $292.8 million (2021), compared with a mean of $275.6 million.
  • Biggest five-year swings in Cost of Revenue: tumbled 131.92% in 2022 and later skyrocketed 354.05% in 2023.
  • Edwards Lifesciences' Cost of Revenue stood at $309.5 million in 2021, then tumbled by 131.92% to -$98.8 million in 2022, then surged by 354.05% to $251.0 million in 2023, then grew by 16.41% to $292.2 million in 2024, then grew by 17.39% to $343.0 million in 2025.
  • The last three reported values for Cost of Revenue were $343.0 million (Q4 2025), $345.2 million (Q3 2025), and $344.4 million (Q2 2025) per Business Quant data.